CASC
LXRX icon

Coppell Advisory Solutions Corp’s Lexicon Pharmaceuticals LXRX Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-113
Closed -$216 – 704
2022
Q4 		$216 Buy
+113
New +$240 ﹤0.01% 1108

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coppell Advisory Solutions Corp's LXRX Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2023, closing a stake of 113 shares — an estimated $216 sold.

Coppell Advisory Solutions Corp first reported a position in LXRX in Q4 2022 and held it in 1 quarter. The position peaked at $216 in Q4 2022. 104 funds tracked by Wall St. Rank hold LXRX as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Lexicon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 113 Lexicon Pharmaceuticals shares in Q1 2023, an estimated $216.
  • Coppell Advisory Solutions Corp first reported a position in Lexicon Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Lexicon Pharmaceuticals position peaked at $216 in Q4 2022.
  • 104 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.